SoCal Flipbooks

Health Matters: Providence St. Jude Medical Center | 3 PLUVICTO operates like a homing missile that looks specifically for PSMA+ antibodies. L ast year Providence St. Jude became one of the first in Southern California to offer an innovative new approach to treating metastatic prostate cancer. And for Barry McKinley, the impact of that new treatment—called Pluvicto—can be measured in many more nights playing softball, days spent sur fing, and weekends dedicated to grandchildren. When he was diagnosed with stage IV prostate cancer in 2017, chemotherapy and hormone therapy successfully controlled it. But by 2022, his PSA numbers were back up in the high 30s and the very aggressive cancer had spread. A new targeted therapy—capable of identifying and killing cells that express PSMA, a prostate cancer biomarker—was showing good results against metastatic prostate cancers in clinical trials. As FDA approval for Pluvicto moved closer, Barry was foremost in the thoughts of David Park, MD, Medical Director of the Providence St. Jude Crosson Cancer Institute. " We had been carefully following the therapy's outcomes and moved quickly to become one of the nation's first approved sites," explains Dr. Park. "There were other treatment options available, including some new clinical trials we had just opened, but this targeted radioisotope had the most potential to reverse the trajectory of Barry's cancer." So, at 7:30 p.m. on a Tuesday night, the phone rang and Barr y got the news that he would be treated with the first-ever molecular-targeted therapy for prostate cancer. "Dr. Park could have waited until the next day to tell me," explains the retired entrepreneur and grandfather of seven. "But he was so excited for me to have this option." After Barry 's first IV infusion of Pluvicto, his PSA numbers dropped 10 points. After his second infusion, they fell another 10—falling even further after the third. Scheduled for three more treatments, one every six weeks, Barry says side effects are very minimal, allowing him to maintain a full schedule of pickleball, family events, serving as a SCORE mentor to help new business owners succeed, and softball games, four to five times a week. Unlike traditional radiation or chemotherapy, which can't distinguish between healthy and cancerous cells, Pluvicto operates like a homing missile that looks specifically for PSMA+ antibodies. "Once in the bloodstream, its search-and-destroy capability can reach prostate cancer cells anywhere in the body," explains Yung Lyou, MD, a Crosson Cancer Institute genitourinary oncologist who specializes in prostate, kidney and bladder cancers. "Pluvicto's radioisotope attaches to the cancer cells and, once absorbed, releases radiation to kill it." Pluvicto is currently approved for PMSA- positive metastatic prostate cancers that are no longer responding to hormone therapy or chemotherapy—a category a growing number of men fall into. Ongoing research at Providence St. Jude Crosson Cancer Institute is evaluating the benefits of using the targeted therapy earlier in treatment. According to Dr. Lyou, therapies like Pluvicto represent an important shift: from treating cancer according to its location, to targeting Continued on next page

• Cover